<DOC>
	<DOCNO>NCT02571842</DOCNO>
	<brief_summary>Currently , treatment option recurrent IgA nephropathy ( IgAN ) conflict largely base expert opinion . Consequently , recent KDIGO clinical practice guideline care kidney transplant recipient conclude definite strategy prevention treatment . However , recurrent IgAN transplant kidney common may contribute graft loss , particular , cresentic formation , extra- endocapillary proliferation present kidney pathology . Herein , investigator assume rituximab , anti-CD20 Ab agent , reduce circulate IgA subsequently decrease rate polymeric form IgA deposition glomerular capillary . Therefore , investigator speculate rituximab may potential effect reduce circulate polymeric form IgA slow progression recurrent IgAN .</brief_summary>
	<brief_title>Rituximab Recurrent IgA Nephropathy</brief_title>
	<detailed_description>Hypothesis : In kidney transplant recipient active endocapillary proliferation pathology recurrent IgAN , intravenous infusion 375mg/m2 rituximab 4 consecutive monthly dose superior conventional therapy reduce 24-hour proteinuria , slow progression recurrent IgAN .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Glomerulonephritis , IGA</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Enalapril</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Any kidney transplant recipient age 18 70 year age able give inform consent GFR 24h Creatinine Clearance ( CrCl ) &gt; 30 ml/min/1.73m² Biopsy proven recurrent IgA nephropathy endocapillary proliferation pattern Clinical histologic evidence IgA combination form glomerulonephritis Clinical evidence cirrhosis , chronic active liver disease know infection hepatitis B , C HIV 24h CrCl &lt; 30 ml/min/1.73m² time screen Active systemic infection history serious infection within one month entry Positive pregnancy test breast feeding time study entry Patients receive &gt; 6 month therapy oral prednisone &gt; 5mg/day glucocorticoid equivalent Live vaccine within 28 day study enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Recurrent IgA nephropathy</keyword>
	<keyword>Rituximab</keyword>
</DOC>